Fundação Pró-Renal Brasil, Centro de Nefrologia Intervencionista, Curitiba, PR, Brasil.
J Bras Nefrol. 2021 Apr-Jun;43(2):263-268. doi: 10.1590/2175-8239-JBN-2020-U001.
The Fistula First Breakthrough Initiative, founded in 2003, was responsible for changing the access profile in the United States, increasing the prevalence of arteriovenous fistulas (AVFs) by 50% and reducing that of arteriovenous grafts (AVGs). However, the concept that AVFs are always the best access for all patients has been challenged. Discussion points are: (1) the questionable survival benefit of AVFs over AVGs, if one takes into account the high rates of primary AVF failure; (2) the potential benefits of using AVGs for greater primary success; and (3) the questionable benefit of AVFs over AVGs in patients with shorter survival, such as the elderly. The high rate of primary failure and maturation procedures leads to prolonged use of catheters, and it is one of the weaknesses of the fistula first strategy. AVGs proved to be better than AVFs as a second access after the failure of a first AVF, and in patients with non-ideal vessels, with greater primary success and reduced catheter times. AVGs appear to have a similar survival to AVFs in patients older than 80 years, with less primary failures and interventions to promote maturation. The most recent KDOQUI guidelines suggest an individualized approach in access planning, taking into account life expectancy, comorbidities and individual vascular characteristics, with the aim of chosing adequate access for the right patient, at the right time, for the right reasons.
瘘管优先突破倡议成立于 2003 年,负责改变美国的通路情况,将动静脉瘘(AVF)的流行率提高了 50%,同时降低了动静脉移植物(AVG)的流行率。然而,AVF 始终是所有患者最佳通路的概念受到了挑战。讨论点包括:(1)如果考虑到较高的原发性 AVF 失败率,AVF 是否比 AVG 具有生存获益;(2)AVG 用于提高初次成功率的潜在益处;以及(3)AVF 在生存时间较短的患者(如老年人)中的获益是否存在疑问。原发性失败和成熟程序的高发生率导致导管的使用时间延长,这是瘘管优先策略的弱点之一。AVG 已被证明在首次 AVF 失败后的第二次通路中优于 AVF,并且在非理想血管的患者中,具有更高的初次成功率和减少的导管时间。在 80 岁以上的患者中,AVG 的存活率与 AVF 相似,原发性失败和促进成熟的干预措施较少。最新的 KDOQUI 指南建议在通路规划中采取个体化方法,考虑预期寿命、合并症和个体血管特征,旨在为合适的患者在合适的时间选择合适的通路。